198 related articles for article (PubMed ID: 9435198)
21. Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia.
Marandi T; Dahl ML; Rägo L; Kiivet R; Sjöqvist F
Eur J Clin Pharmacol; 1997; 53(3-4):257-60. PubMed ID: 9476041
[TBL] [Abstract][Full Text] [Related]
22. CYP2C19 genotyping and associated mephenytoin hydroxylation polymorphism in a Canadian Inuit population.
Jurima-Romet M; Goldstein JA; LeBelle M; Aubin RA; Foster BC; Walop W; Rode A
Pharmacogenetics; 1996 Aug; 6(4):329-39. PubMed ID: 8873219
[TBL] [Abstract][Full Text] [Related]
23. Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population.
Bathum L; Skjelbo E; Mutabingwa TK; Madsen H; Hørder M; Brøsen K
Br J Clin Pharmacol; 1999 Sep; 48(3):395-401. PubMed ID: 10510152
[TBL] [Abstract][Full Text] [Related]
24. Frequencies of defective CYP2C19 alleles in a Hong Kong Chinese population: detection of the rare allele CYP2C19*4.
Garcia-Barceló M; Chow LY; Kum Chiu HF; Wing YK; Shing Lee DT; Lam KL; Waye MM
Clin Chem; 1999 Dec; 45(12):2273-4. PubMed ID: 10585366
[No Abstract] [Full Text] [Related]
25. Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism.
Goldstein JA; Blaisdell J
Methods Enzymol; 1996; 272():210-8. PubMed ID: 8791779
[No Abstract] [Full Text] [Related]
26. Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent.
Xie HG; Kim RB; Stein CM; Wilkinson GR; Wood AJ
Br J Clin Pharmacol; 1999 Sep; 48(3):402-8. PubMed ID: 10510153
[TBL] [Abstract][Full Text] [Related]
27. Debrisoquin and S-mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population.
Marandi T; Dahl ML; Kiivet RA; Rägo L; Sjöqvist F
Pharmacol Toxicol; 1996 May; 78(5):303-7. PubMed ID: 8737964
[TBL] [Abstract][Full Text] [Related]
28. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences.
Tamminga WJ; Wemer J; Oosterhuis B; Weiling J; Wilffert B; de Leij LF; de Zeeuw RA; Jonkman JH
Eur J Clin Pharmacol; 1999 May; 55(3):177-84. PubMed ID: 10379632
[TBL] [Abstract][Full Text] [Related]
29. [Genetic polymorphism of the CYP2C subfamily].
Chiba K
Nihon Yakurigaku Zasshi; 1998 Jul; 112(1):15-21. PubMed ID: 9755458
[TBL] [Abstract][Full Text] [Related]
30. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world.
Xie HG; Stein CM; Kim RB; Wilkinson GR; Flockhart DA; Wood AJ
Pharmacogenetics; 1999 Oct; 9(5):539-49. PubMed ID: 10591534
[TBL] [Abstract][Full Text] [Related]
31. Evidence that poor metabolizers of (S)-mephenytoin could be identified by haplotypes of CYP2C19 in Japanese.
Takakubo F; Kuwano A; Kondo I
Pharmacogenetics; 1996 Jun; 6(3):265-7. PubMed ID: 8807668
[TBL] [Abstract][Full Text] [Related]
32. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population.
Roh HK; Dahl ML; Tybring G; Yamada H; Cha YN; Bertilsson L
Pharmacogenetics; 1996 Dec; 6(6):547-51. PubMed ID: 9014204
[TBL] [Abstract][Full Text] [Related]
33. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study.
Balian JD; Sukhova N; Harris JW; Hewett J; Pickle L; Goldstein JA; Woosley RL; Flockhart DA
Clin Pharmacol Ther; 1995 Jun; 57(6):662-9. PubMed ID: 7781266
[TBL] [Abstract][Full Text] [Related]
34. Identification and functional characterization of new potentially defective alleles of human CYP2C19.
Blaisdell J; Mohrenweiser H; Jackson J; Ferguson S; Coulter S; Chanas B; Xi T; Ghanayem B; Goldstein JA
Pharmacogenetics; 2002 Dec; 12(9):703-11. PubMed ID: 12464799
[TBL] [Abstract][Full Text] [Related]
35. Biochemistry and molecular biology of the human CYP2C subfamily.
Goldstein JA; de Morais SM
Pharmacogenetics; 1994 Dec; 4(6):285-99. PubMed ID: 7704034
[TBL] [Abstract][Full Text] [Related]
36. S-mephenytoin 4-hydroxylase is inherited as an autosomal-recessive trait in Japanese families.
Ward SA; Goto F; Nakamura K; Jacqz E; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1987 Jul; 42(1):96-9. PubMed ID: 3595072
[TBL] [Abstract][Full Text] [Related]
37. Genetic polymorphism of S-mephenytoin 4'-hydroxylation.
Daniel HI; Edeki TI
Psychopharmacol Bull; 1996; 32(2):219-30. PubMed ID: 8783891
[TBL] [Abstract][Full Text] [Related]
38. P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism.
Hadama A; Ieiri I; Morita T; Kimura M; Urae A; Irie S; Kaneda T; Mamiya K; Tashiro N; Higuchi S; Otsubo K
Ther Drug Monit; 2001 Apr; 23(2):115-8. PubMed ID: 11294510
[TBL] [Abstract][Full Text] [Related]
39. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe.
Masimirembwa C; Bertilsson L; Johansson I; Hasler JA; Ingelman-Sundberg M
Clin Pharmacol Ther; 1995 Jun; 57(6):656-61. PubMed ID: 7781265
[TBL] [Abstract][Full Text] [Related]
40. The relationship between phenytoin pharmacokinetics and the CYP2C19 genotype in Japanese epileptic patients.
Watanabe M; Iwahashi K; Kugoh T; Suwaki H
Clin Neuropharmacol; 1998; 21(2):122-6. PubMed ID: 9579299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]